Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Gilead Sciences
Gilead Sciences
Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table
Fierce Pharma
Wed, 02/22/23 - 06:54 pm
Gilead Sciences
legal
HIV
antitrust
Teva Pharmaceutical
JNJ
Gilead reports positive data from urothelial cancer therapy trial cohorts
Clinical Trials Arena
Mon, 02/20/23 - 12:51 pm
Gilead Sciences
Trodelvy
metastatic urothelial cancer
clinical trials
Gilead's Trodelvy snags vital breast cancer nod
Fierce Pharma
Mon, 02/6/23 - 10:44 am
Gilead Sciences
FDA
Trodelvy
breast cancer
HR-positive HER-negative breast cancer
Oncology, HIV sales lift Gilead’s revenues by 2%
Medical Marketing and Media
Thu, 02/2/23 - 11:09 pm
Gilead Sciences
earnings
HIV
oncology
hepatitis C
Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program
Fierce Biotech
Wed, 02/1/23 - 10:30 am
Gilead Sciences
Matinas BioPharma
COVID-19
antivirals
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Thu, 01/26/23 - 10:40 am
Gilead Sciences
CAR-T
Yescarta
UK
NICE
Kite Pharma
Novartis
blood cancer
Gilead Sciences to provide Trodelvy for Strata PATH trial
Clinical Trials Arena
Thu, 01/19/23 - 07:48 pm
Gilead Sciences
Strata Oncology
Trodelvy
clinical trials
Gilead fosters growth with plans for new research center in California hometown
Fierce Biotech
Wed, 01/18/23 - 11:04 pm
Gilead Sciences
R&D
California
Big caps bounce back for biopharma
EP Vantage
Mon, 01/16/23 - 11:14 am
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Three TIGIT players look to surprise in 2023
EP Vantage
Fri, 01/13/23 - 10:06 am
anti-TIGIT
Roche
Merck
Gilead Sciences
Arcus Biosciences
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
BioPharma Dive
Tue, 01/10/23 - 10:47 am
JPMHC 2023
vaccines
COVID-19
Moderna Therapeutics
Pfizer
Gilead Sciences
5 FDA decisions to watch in the first quarter
BioPharma Dive
Mon, 01/9/23 - 10:27 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
BioPharma Dive
Wed, 01/4/23 - 10:11 am
FDA
drug approvals
HIV
lymphoma
multiple sclerosis
Gilead Sciences
Roche
TG Therapeutics
Gilead, EVOQ Unite on 'Potential Breakthrough' Treatment for RA, Lupus
BioSpace
Tue, 01/3/23 - 10:28 pm
Gilead Sciences
Evoq Therapeutics
lupus
rheumatoid arthritis
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Gilead buys remaining rights to Jounce’s immunotherapy GS-1811
Medical Marketing and Media
Wed, 12/28/22 - 08:39 pm
Gilead Sciences
Jounce Therapeutics
GS-1811
Gilead goes long-acting in HIV
EP Vantage
Fri, 12/23/22 - 10:35 am
Gilead Sciences
lenacapavir
HIV
FDA
Kite swoops in to buy Carl June-founded Tmunity, gaining key to Penn's CAR-T research apparatus
Fierce Biotech
Tue, 12/20/22 - 11:17 am
Kite Pharma
Gilead Sciences
M&A
CAR-T
Tmunity
Carl June
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Fierce Biotech
Fri, 12/9/22 - 10:46 am
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Gilead Sciences
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »